Molecular profiling in the age of cancer genomics

Expert Review of Molecular Diagnostics

Volumn 8, Issue 3, 2008, Pages 263-276

  Lin, Jimmy ^a   Li, Meng ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Cancer genomics; Molecular diagnostics; Proteomics; Transcriptomics

Indexed keywords

BIOLOGICAL MARKER; FLUOROURACIL; MITOGEN ACTIVATED PROTEIN KINASE 14; PROSTATE SPECIFIC ANTIGEN;

BREAST CANCER; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CARCINOGENESIS; COLORECTAL TUMOR; DISEASE MARKER; DNA METHYLATION; DNA MICROARRAY; DNA SEQUENCE; DNA TEMPLATE; GENE AMPLIFICATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE TECHNOLOGY; GENETIC COMPLEMENTATION; GENOMICS; HUMAN; LUNG CANCER; NONHUMAN; NUCLEOTIDE SEQUENCE; OVARY CANCER; POLYMERASE CHAIN REACTION; PROSTATE CANCER; PROTEOMICS; REVIEW; TRANSCRIPTOMICS; TUMOR GENE;

GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENOME, HUMAN; HUMANS; NEOPLASMS; PROTEOMICS;

EID: 44249090038     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.3.263     Document Type: Review

References (115)

1. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc. Natl Acad. Sci. USA 74(12), 5463-5467 (1977).
2. Paegel BM, Emrich CA, Wedemayer GJ, Scherer JR, Mathies RA. High throughput DNA sequencing with a microfabricated 96-lane capillary array electrophoresis bioprocessor. Proc. Natl Acad. Sci. USA 99(2), 574-579 (2002).
3. Paegel BM, Blazej RG, Mathies RA. Microfluidic devices for DNA sequencing: sample preparation and electrophoretic analysis. Curr. Opin. Biotechnol. 14(1), 42-50 (2003).
4. Drmanac S, Kita D, Labat I et al. Accurate sequencing by hybridization for DNA diagnostics and individual genomics. Nat. Biotechnol. 16(1), 54-58 (1998).
5. Drmanac R, Drmanac S, Baier J et al. DNA sequencing by hybridization with arrays of samples or probes. Methods Mol. Biol. 170, 173-179 (2001).
6. Lipshutz RJ, Morris D, Chee M et al. Using oligonucleotide probe arrays to access genetic diversity. Biotechniques 19(3), 442-447 (1995).
7. Mitra RD, Shendure J, Olejnik J, Edyta-Krzymanska-Olejnik, Church GM. Fluorescent in situ sequencing on polymerase colonies. Anal. Biochem. 320(1), 55-65 (2003).
8. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science 281(5375), 363, 365 (1998).
9. Ronaghi M. Pyrosequencing sheds light on DNA sequencing. Genome Res. 11(1), 3-11 (2001).
10. Gharizadeh B, Nordstrom T, Ahmadian A, Ronaghi M, Nyren P. Long-read pyrosequencing using pure 2′-deoxyadenosine-5′-O′-(1- thiotriphosphate) Sp-isomer. Anal. Biochem. 301(1), 82-90 (2002).
11. Brenner S, Johnson M, Bridgham J et al. Gene expression analysis by massively parallel signature sequencing (MPSS) on microbead arrays. Nat. Biotechnol. 18(6), 630-634 (2000).
12. Reinartz J, Bruyns E, Lin JZ et al. Massively parallel signature sequencing (MPSS) as a tool for in-depth quantitative gene expression profiling in all organisms. Brief Funct. Genomic. Proteomic. 1(1), 95-104 (2002).
13. Leamon JH, Lee WL, Tartaro KR et al. A massively parallel PicoTiterPlate based platform for discrete picoliter-scale polymerase chain reactions. Electrophoresis 24(21), 3769-3777 (2003).
14. Mitra RD, Church GM. In situ localized amplification and contact replication of many individual DNA molecules. Nucleic Acids Res. 27(24), E34 (1999).
15. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc. Natl Acad. Sci. USA 100(15), 8817-8822 (2003).
16. Margulies M, Egholm M, Altman WE et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437(7057), 376-380 (2005).
17. Shendure J, Porreca GJ, Reppas NB et al. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 309(5741), 1728-1732 (2005).
18. Bennett ST, Barnes C, Cox A, Davies L, Brown C. Toward the 1,000 dollars human genome. Pharmacogenomics 6(4), 373-382 (2005).
19. Deamer DW, Branton D. Characterization of nucleic acids by nanopore analysis. Acc. Chem. Res. 35(10), 817-825 (2002).
20. Li J, Gershow M, Stein D, Brandin E, Golovchenko JA. DNA molecules and configurations in a solid-state nanopore microscope. Nat. Mater. 2(9), 611-615 (2003).
21. Deamer DW, Akeson M. Nanopores and nucleic acids: prospects for ultrarapid sequencing. Trends Biotechnol. 18(4), 147-151 (2000).
22. Winters-Hilt S, Vercoutere W, DeGuzman VS et al. Highly accurate classification of Watson-Crick basepairs on termini of single DNA molecules. Biophys. J. 84(2 Pt 1), 967-976 (2003).
23. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 417(6892), 949-954 (2002).
24. Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554 (2004).
25. Bardelli A, Parsons DW, Silliman N et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 300(5621), 949 (2003).
26. Parsons DW, Wang TL, Samuels Y et al. Colorectal cancer: mutations in a signalling pathway. Nature 436(7052), 792 (2005).
27. Greenman C, Stephens P, Smith R et al. Patterns of somatic mutation in human cancer genomes. Nature 446(7132), 153-158 (2007).
28. Sjoblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 314(5797), 268-274 (2006).
29. Diehl F, Li M, Dressman D et al. Detection and quantification of mutations in the plasma of patients with colorectal tumors. Proc. Natl Acad. Sci. USA 102(45), 16368-16373 (2005).
30. Li M, Diehl F, Dressman D, Vogelstein B, Kinzler KW. BEAMing up for detection and quantification of rare sequence variants. Nat. Methods 3(2), 95-97 (2006).
31. Schena M, Shalon D, Davis RW, Brown PO. Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science 270(5235), 467-470 (1995).
32. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science 270(5235), 484-487 (1995).
33. Cuperlovic-Culf M, Belacel N, Culf AS, Ouellette RJ. Microarray analysis of alternative splicing. OMICS 10(3), 344-357 (2006).
34. Kim JB, Porreca GJ, Song L et al. Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science 316(5830), 1481-1484 (2007).
35. DeRisi J, Penland L, Brown PO et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat. Genet. 14(4), 457-460 (1996).
36. Golub TR, Slonim DK, Tamayo P et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286(5439), 531-537 (1999).
37. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403(6769), 503-511 (2000).
38. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406(6795), 536-540 (2000).
39. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406(6797), 747-752 (2000).
40. Bhattacharjee A, Richards WG, Staunton J et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc. Natl Acad. Sci. USA 98(24), 13790-13795 (2001).
41. Dyrskjot L, Thykjaer T, Kruhoffer M et al. Identifying distinct classes of bladder carcinoma using microarrays. Nat. Genet. 33(1), 90-96 (2003).
42. Ramaswamy S, Tamayo P, Rifkin R et al. Multiclass cancer diagnosis using tumor gene expression signatures. Proc. Natl Acad. Sci. USA 98(26), 15149-15154 (2001).
43. Su AI, Welsh JB, Sapinoso LM et al. Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res. 61(20), 7388-7393 (2001).
44. Bullinger L, Dohner K, Bair E et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N. Engl. J. Med. 350(16), 1605-1616 (2004).
45. Valk PJ, Verhaak RG, Beijen MA et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N. Engl. J. Med. 350(16), 1617-1628 (2004).
46. Rosenwald A, Wright G, Chan WC et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346(25), 1937-1947 (2002).
47. Lossos IS, Czerwinski DK, Alizadeh AA et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N. Engl. J. Med. 350(18), 1828-1837 (2004).
48. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412(6849), 822-826 (2001).
49. Chen HY, Yu SL, Chen CH et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N. Engl. J. Med. 356(1), 11-20 (2007).
50. West M, Blanchette C, Dressman H et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc. Natl Acad. Sci. USA 98(20), 11462-11467 (2001).
51. van 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871), 530-536 (2002).
52. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 347(25), 1999-2009 (2002).
53. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351(27), 2817-2826 (2004).
54. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365(9460), 671-679 (2005).
55. Chang HY, Nuyten DS, Sneddon JB et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc. Natl Acad. Sci. USA 102(10), 3738-3743 (2005).
56. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N. Engl. J. Med. 355(6), 560-569 (2006).
57. Kudoh K, Ramanna M, Ravatn R et al. Monitoring the expression profiles of doxorubicin-induced and doxorubicin-resistant cancer cells by cDNA microarray. Cancer Res. 60(15), 4161-4166 (2000).
58. Scherf U, Ross DT, Waltham M et al. A gene expression database for the molecular pharmacology of cancer. Nat. Genet. 24(3), 236-244 (2000).
59. Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. 6(4), 1322-1327 (2000).
60. Kornmann M, Schwabe W, Sander S et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin. Cancer Res. 9(11), 4116-4124 (2003).
61. Ciaparrone M, Quirino M, Schinzari G et al. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil. Oncology 70(5), 366-377 (2006).
62. Bertone P, Stolc V, Royce TE et al. Global identification of human transcribed sequences with genome tiling arrays. Science 306(5705), 2242-2246 (2004).
63. Porkka KP, Pfeiffer MJ, Waltering KK et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 67(13), 6130-6135 (2007).
64. Yanaihara N, Caplen N, Bowman E et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9(3), 189-198 (2006).
65. Calin GA, Liu CG, Sevignani C et al. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Natl Acad. Sci. USA 101(32), 11755-11760 (2004).
66. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 435(7043), 834-838 (2005).
67. Cummins JM, He Y, Leary RJ et al. The colorectal microRNAome. Proc. Natl Acad. Sci. USA 103(10), 3687-3692 (2006).
68. Stamey TA, Yang N, Hay AR et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N. Engl. J. Med. 317(15), 909-916 (1987).
69. Reynoso G, Chu TM, Holyoke D et al. Carcinoembryonic antigen in patients with different cancers. JAMA 220(3), 361-365 (1972).
70. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin. Chem. 45(9), 1628-1650 (1999).
71. Balamurugan S, Obubuafo A, Soper SA, Spivak DA. Surface immobilization methods for aptamer diagnostic applications. Anal. Bioanal. Chem. 390(4), 1009-1021 (2008).
72. Franzen B, Iwabuchi H, Kato H, Lindholm J, Auer G. Two-dimensional polyacrylamide gel electrophoresis of human lung cancer: qualitative aspects of tissue preparation in relation to histopathology. Electrophoresis 12(7-8), 509-515 (1991).
73. Okuzawa K, Franzen B, Lindholm J et al. Characterization of gene expression in clinical lung cancer materials by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 15(3-4), 382-390 (1994).
74. Zhukov TA, Johanson RA, Cantor AB, Clark RA, Tockman MS. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. Lung Cancer 40(3), 267-279 (2003).
75. Li C, Zhan X, Li M et al. Proteomic comparison of two-dimensional gel electrophoresis profiles from human lung squamous carcinoma and normal bronchial epithelial tissues. Genomics Proteomics Bioinformatics 1(1), 58-67 (2003).
76. Li C, Chen Z, Xiao Z et al. Comparative proteomics analysis of human lung squamous carcinoma. Biochem. Biophys. Res. Commun. 309(1), 253-260 (2003).
77. Wu X, Xiao Z, Chen Z et al. Differential analysis of two-dimension gel electrophoresis profiles from the normal-metaplasia-dysplasia-carcinoma tissue of human bronchial epithelium. Pathol. Int. 54(10), 765-773 (2004).
78. Chen G, Gharib TG, Huang CC et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin. Cancer Res. 8(7), 2298-2305 (2002).
79. Hirano T, Fujioka K, Franzen B et al. Relationship between TA01 and TA02 polypeptides associated with lung adenocarcinoma and histocytological features. Br. J. Cancer 75(7), 978-985 (1997).
80. Meyerson M, Carbone D. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J. Clin. Oncol. 23(14), 3219-3226 (2005).
81. Luo Y, Zhang J, Liu Y et al. Comparative proteome analysis of breast cancer and normal breast. Mol. Biotechnol. 29(3), 233-244 (2005).
82. Celis JE, Moreira JM, Cabezon T et al. Identification of extracellular and intracellular signaling components of the mammary adipose tissue and its interstitial fluid in high risk breast cancer patients: toward dissecting the molecular circuitry of epithelial-adipocyte stromal cell interactions. Mol. Cell. Proteomics 4(4), 492-522 (2005).
83. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin. Chem. 48(8), 1296-1304 (2002).
84. Rui Z, Jian-Guo J, Yuan-Peng T, Hai P, Bing-Gen R. Use of serological proteomic methods to find biomarkers associated with breast cancer. Proteomics 3(4), 433-439 (2003).
85. Carter D, Douglass JF, Cornellison CD et al. Purification and characterization of the mammaglobin/lipophilin B complex, a promising diagnostic marker for breast cancer. Biochemistry 41(21), 6714-6722 (2002).
86. Li J, Orlandi R, White CN et al. Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. Clin. Chem. 51(12), 2229-2235 (2005).
87. Mathelin C, Cromer A, Wendling C, Tomasetto C, Rio MC. Serum biomarkers for detection of breast cancers: a prospective study. Breast Cancer Res. Treat. 96(1), 83-90 (2006).
88. Somiari RI, Somiari S, Russell S, Shriver CD. Proteomics of breast carcinoma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 815(1-2), 215-225 (2005).
89. Petricoin EF, Ardekani AM, Hitt BA et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359(9306), 572-577 (2002).
90. Conrads TP, Fusaro VA, Ross S et al. High-resolution serum proteomic features for ovarian cancer detection. Endocr. Relat. Cancer 11(2), 163-178 (2004).
91. Ornstein DK, Rayford W, Fusaro VA et al. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml. J. Urol. 172(4 Pt 1), 1302-1305 (2004).
92. Zheng Y, Xu Y, Ye B et al. Prostate carcinoma tissue proteomics for biomarker discovery. Cancer 98(12), 2576-2582 (2003).
93. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 3(6), 415-428 (2002).
94. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylationspecific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl Acad. Sci. USA 93(18), 9821-9826 (1996).
95. Eads CA, Danenberg KD, Kawakami K et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. 28(8), E32 (2000).
96. Xiong Z, Laird PW. COBRA: a sensitive and quantitative DNA methylation assay. Nucleic Acids Res. 25(12), 2532-2534 (1997).
97. Gonzalgo ML, Jones PA. Rapid quantitation of methylation differences at specific sites using methylation-sensitive single nucleotide primer extension (Ms-SNuPE). Nucleic Acids Res. 25(12), 2529-2531 (1997).
98. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301(5895), 89-92 (1983).
99. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N. Engl. J. Med. 349(21), 2042-2054 (2003).
100. Esteller M, Sanchez-Cespedes M, Rosell R et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res. 59(1), 67-70 (1999).
101. Grady WM, Rajput A, Lutterbaugh JD, Markowitz SD. Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Res. 61(3), 900-902 (2001).
102. Usadel H, Brabender J, Danenberg KD et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res. 62(2), 371-375 (2002).
103. Wong IH, Zhang J, Lai PB, Lau WY, Lo YM. Quantitative analysis of tumor-derived methylated p16INK4a sequences in plasma, serum, and blood cells of hepatocellular carcinoma patients. Clin. Cancer Res. 9(3), 1047-1052 (2003).
104. Chen WD, Han ZJ, Skoletsky J et al. Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. J. Natl Cancer Inst. 97(15), 1124-1132 (2005).
105. Hoque MO, Begum S, Topaloglu O et al. Quantitation of promoter methylation of multiple genes in urine DNA and bladder cancer detection. J. Natl Cancer Inst. 98(14), 996-1004 (2006).
106. Hoque MO, Feng Q, Toure P et al. Detection of aberrant methylation of four genes in plasma DNA for the detection of breast cancer. J. Clin. Oncol. 24(26), 4262-4269 (2006).
107. Hu M, Yao J, Cai L et al. Distinct epigenetic changes in the stromal cells of breast cancers. Nat. Genet. 37(8), 899-905 (2005).
108. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J. Mol. Biol. 215(3), 403-410 (1990).
109. Altschul SF, Madden TL, Schaffer AA et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25(17), 3389-3402 (1997).
110. Kent WJ. BLAT - the BLAST-like alignment tool. Genome Res. 12(4), 656-664 (2002).
111. Finn RD, Tate J, Mistry J et al. The Pfam protein families database. Nucleic Acids Res. 36(Database issue), D281-D288 (2008).
112. Hsu F, Pringle TH, Kuhn RM et al. The UCSC Proteome Browser. Nucleic Acids Res. 33(Database issue), D454-D458 (2005).
113. Boutet E, Lieberherr D, Tognolli M, Schneider M, Bairoch A. UniProtKB/Swiss-Prot: the manually annotated section of the UniProt knowledgebase. Methods Mol. Biol. 406, 89-112 (2007).
114. Lo Conte L, Ailey B, Hubbard TJ et al. SCOP: a structural classification of proteins database. Nucleic Acids Res. 28(1), 257-259 (2000).
115. Holm L, Sander C. The FSSP database: fold classification based on structure-structure alignment of proteins. Nucleic Acids Res. 24(1), 206-209 (1996).